Even though Alzheimer’s Disease is the most common form of dementia, it is also a complication of Parkinson’s disease, Huntington’s disease and a further cause is Lewy Body dementia. Consider this:
- Seventy percent of dementia cases are due to Alzheimer’s disease
- It is estimated that one in six women over the age of 55 will develop dementia, compared to one in ten men.
As much as dementia and Alzheimer’s disease research results sound promising, we are cautiously optimistic about the findings that currently dictate the way it is diagnosed and treated. To date, we have research results that are encouraging:
- In 2016, researchers in the US found a direct correlation between dementia and heart health. In a study published by the New England Journal of Medicine, researchers found that addressing cardiovascular disease lowered the risk of dementia. (1), (2)
- A collaboration between scientists in the US and Australia regarding dementia-related diseases showed that brain inflammation is also a major cause. (3)
- Researchers from the University of Cambridge and Lund University in Sweden discovered that small clumps of proteins called oligomers kill healthy nerve cells. This is particularly relevant in the development of drugs aimed at targeting these toxic particles. (4)
- New technology in brain imaging is showing specific protein clusters, critical to the diagnosis of Alzheimer’s Disease. (5)
photo by USF Health
Dr. Amy Borenstein has been studying Alzheimer’s disease for over 30 years, beginning with one of the early case-control studies of this disease. Since 1988, she has been funded by the National Institute on Aging as well as private sources to carry out a wide range of research in different countries and ethnicities focusing on Alzheimer’s disease and related dementias. Dr. Borenstein has published extensively in the medical literature and is recognized as a leading epidemiologist in the study of Alzheimer’s disease.
Author of “Alzheimer’s Disease: Life Course Perspectives on Risk Reduction”,Dr. Borenstein will address how dementia is impacting the economic and social fabric of an increasing number of countries as the world population ages. She will give a clinical overview of the major subtypes of dementia and the important risk factors for Alzheimer’s Disease and other dementias. She will also discuss promising ongoing trials of antibodies against the Alzheimer protein beta-amyloid. Most importantly, Dr. Borenstein will outline lifestyle changes that may delay the onset of Alzheimer’s and other dementias.
|Dr. Pamela Maher, photo from the Salk Institute|
Dr. Pamela Maher has studied the nervous system throughout her career and has identified several natural products that mimic the effects of protein growth factors in the nervous system. Her recent work has focused on identifying other natural products that are effective against brain diseases, improving the natural products already identified using medicinal chemistry, modifying the products to allow penetration of the blood/brain barrier and characterizing their molecular targets so as to provide additional approaches to the treatment of brain diseases.
Dr. Maher will first discuss the rationale behind her approach to the development of novel therapeutics for the treatment of Alzheimer’s Disease and other dementias. She will then provide some examples of the use of this approach including her recent studies of a plant product the were featured in the Union Tribune. Finally, she will summarize where we are right now and what she hopes to accomplish in the future.
The most important service the Howell Foundation can provide is education through the presentation of vital health information. We are moving closer to a cure. Until that day, we must focus on prevention when discussing Alzheimer’s and dementia.